	US 12,257,282 B2
	Mixtures and formulations
Justas Barauskas, Lund (SE); Catalin Nistor, Lund (SE); and Markus Johnsson, Lund (SE)
Assigned to CAMARUS AB, Lund (SE)
Filed by CAMURUS AB, Lund (SE)
Filed on Jan. 27, 2022, as Appl. No. 17/586,014.
Application 17/586,014 is a continuation of application No. 16/335,487, granted, now 11,241,476, previously published as PCT/EP2017/074418, filed on Sep. 26, 2017.
Claims priority of application No. 16190892 (EP), filed on Sep. 27, 2016; and application No. 1616366 (GB), filed on Sep. 27, 2016.
Prior Publication US 2022/0257694 A1, Aug. 18, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/08 (2019.01); A61K 9/00 (2006.01); A61K 47/10 (2017.01); A61K 47/14 (2017.01); A61K 47/18 (2017.01); A61K 47/24 (2006.01)

CPC A61K 38/08 (2013.01) [A61K 9/0019 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61K 47/183 (2013.01); A61K 47/186 (2013.01); A61K 47/24 (2013.01)]

38 Claims

1. A pre-formulation comprising:

i) a lipid mixture comprising:

a) glycerol dioleate (GDO);

b) at least one phosphatidyl choline (PC); and

c) at least one biocompatible, organic solvent; and

ii) ethylenediaminetetraacetic acid (EDTA) and an alkylamine selected from the group consisting of ethanolamine (ETA), diethanolamine (DiETA), meglumine, tris-hydroxymethylamine (TRIS), ethylenediamine, and serinol;

wherein the pre-formulation has a water content in the range of 0 to 1.0 wt %,

wherein the molar ratio of EDTA: alkylamine is 1:≥3.0 for ETA, DiETA, meglumine, TRIS, and serinol, and 1:≥2.0 for ethylenediamine.